The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $8.64

Today's change-0.17 -1.93%
Updated February 5 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $8.64

Today's change-0.17 -1.93%
Updated February 5 4:00 PM -5GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc crosses below 20-day moving average

Vanda Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.17 or 1.93% to (U.S.)$8.64 and crossing below its 20-day moving average. Over the last five days, shares have gained 1.29%, but are down 7.20% for the last year to date. Shares have underperformed the S&P 500 by 16.48% during the last year.

Key company metrics

  • Open(U.S.) $8.77
  • Previous close(U.S.) $8.81
  • High(U.S.) $8.78
  • Low(U.S.) $8.51
  • Bid / Ask(U.S.) $1.00 / (U.S.) $9.65
  • YTD % change-7.20%
  • Volume553,198
  • Average volume (10-day)634,384
  • Average volume (1-month)636,592
  • Average volume (3-month)759,469
  • 52-week range(U.S.) $8.00 to (U.S.) $14.50
  • Beta1.70
  • Trailing P/E7.37×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.17
Updated February 5 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+47.78%

Based on its net profit margin of 47.78%, Vanda Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue28282215
Total other revenue--------
Total revenue28282215
Gross profit22221715
Total cost of revenue7651
Total operating expense383332-54
Selling / general / administrative18181917
Research & development10645
Depreciation / amortization3341
Interest expense (income), net operating--------
Unusual expense (income)-------78
Other operating expenses, total--------
Operating income-10-5-1070
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-9-5-1070
Income after tax-9-5-1070
Income tax, total------0
Net income-9-5-1070
Total adjustments to net income--------
Net income before extra. items-9-5-1070
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-9-5-1070
Inc. avail. to common incl. extra. items-9-5-1070
Diluted net income-9-5-1070
Dilution adjustment--000
Diluted weighted average shares42424239
Diluted EPS excluding extraordinary itemsvalue per share-0.22-0.13-0.241.77
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.22-0.13-0.24-0.20